SINGAPORE – Bioactivx® (BAX), a biomaterials startup pioneering next-generation regenerative implants has closed its seed funding round led by Cocoon Capital, with participation from global strategic investors.  

The funding will fast-track the company’s clinical and regulatory pathway for its flagship innovation, Bioactiv® Matrix – a fully synthetic, bio-inspired skin substitute that promotes faster healing, minimal scarring, and zero risk of infection.

Each year, more than 11 million people suffer burn injuries worldwide, resulting in over 180,000 deaths according to the World Health Organization. Current treatments often rely on animal-derived collagen or skin grafts, which come with high infection risks, inconsistent results, and ethical or cultural barriers.

Bioactivx takes a completely new approach using a synthetic regenerative platform that mimics the body’s natural healing process without relying on animal materials. This means no infection risk, no cold-chain storage, and no cultural restrictions, including regions where porcine- or bovine-derived products are restricted for cultural or religious reasons, making it suitable for hospitals, military, and remote environments globally.​

In pre-clinical studies, Bioactiv® Matrix achieved full wound closure in just seven days and showed no inflammation by day 15, outperforming leading collagen-based products. Early human trials also demonstrated faster recovery and cleaner healing than the current standard of care.

“Our mission is to move beyond animal-based materials and create a new class of regenerative implants that are safe, synthetic, and scalable,” said Dr. Peili Teo, Co-founder and Director for Technology of Bioactivx®. “This investment will accelerate regulatory approval for Bioactiv® Matrix and expand our pipeline to treat more types of wounds and tissue injuries.”

“Bioactivx is solving a massive unmet need in wound care,” said Zongxi Sia, Investment Director at Cocoon Capital. “Their synthetic biomaterial platform could transform regenerative medicine – offering safer, more effective, and culturally inclusive solutions.”

With the new funding, Bioactivx will:

• Advance Bioactiv® Matrix toward global regulatory approval and commercialization
  
• Develop new products such as Bioactiv® Foam (for acute and chronic wounds) and Bioactiv® Cellulose (for ulcers and long-term care)
  
• Scale up its Singapore production facility built to ISO 13485 standards